VKORC1-1639A Allele Influences Warfarin Maintenance Dosage Among Blacks Receiving Warfarin Anticoagulation: A Retrospective Cohort Study

References

• Wardrop D , KeelingD . The story of the discovery of heparin and warfarin . Br. J. Haematol.141 ( 6 ), 757 – 763 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Ansell J , HirshJ, HylekE, JacobsonA, CrowtherM, PalaretiG . Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) . Chest133 ( Suppl. 6 ), S160 – S198 ( 2008 ).
   Google Scholar
• Fauchier L , PhilippartR, ClementyNet al. How to define valvular atrial fibrillation? Arch. Cardiovasc. Dis. 108 ( 10 ), 530 – 539 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Hirsh J , DalenJ, AndersonDRet al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range . Chest119 ( Suppl. 1 ), S8 – S21 ( 2001 ).
   Web of Science ®Google Scholar
• Oden A , FahlenM, HartRG . Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal . Thromb. Res.117 ( 5 ), 493 – 499 ( 2006 ).
   PubMedGoogle Scholar
• Budnitz DS , PollockDA, WeidenbachKN, MendelsohnAB, SchroederTJ, AnnestJL . National surveillance of emergency department visits for outpatients adverse drug events . JAMA296 ( 15 ), 1858 – 1866 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Furuya H , Fernandez-SalgueroP, GregoryWet al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirements in patients undergoing anticoagulant therapy . Pharmacogenetics5 ( 6 ), 389 – 392 ( 1995 ).
   PubMedGoogle Scholar
• Aithal GP , DayCP, KestevenPJL, DalyAK . Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications . Lancet353 ( 9154 ), 717 – 719 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Higashi MK , VeenstraDL, KondoLMet al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy . JAMA287 ( 13 ), 1690 – 1698 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Limdi NA , ArnettDK, GoldsteinJAet al. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European–Americans and African–Americans . Pharmacogenomics9 ( 5 ), 511 – 526 ( 2008a ).
   PubMed Web of Science ®Google Scholar
• Cavallari LH , LangaeeTY, MomaryKMet al. Genetic and clinical predictors of warfarin dose requirements in African Americans . Clin. Pharmacol. Ther.87 ( 4 ), 459 – 464 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Liu Y , JeongH, TakahashiHet al. Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism . Clin. Pharmacol. Ther.91 ( 4 ), 660 – 665 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Li T , ChangC-Y, JinD-Y, LiPJ, KhvorovaA, StaffordDW . Identification of the gene for vitamin K epoxide reductase . Nature427 ( 6974 ), 541 – 544 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Rost S , FreginA, IvaskeviciusVet al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 . Nature427 ( 6974 ), 537 – 541 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• D’Andrea G , D’AmbrosioRL, Di PernaPet al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulation effect of warfarin . Blood105 ( 2 ), 645 – 649 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Geisen C , WatzkaM, SittingerKet al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation . Thromb. Haemost.94 ( 4 ), 773 – 779 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Rieder MJ , ReinerAP, GageBFet al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose . N. Engl. J. Med.352 ( 22 ), 2285 – 2293 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Schelleman H , ChenZ, KealeyCet al. Warfarin response and vitamin K epoxyde reductase complex 1 in African Americans and Caucasians . Clin. Pharmacol. Ther.81 ( 5 ), 742 – 747 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Wang D , ChenH, MomaryKMet al. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement . Blood112 ( 4 ), 1013 – 1021 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Perera MA , GamazonE, CavallariLHet al. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans . Clin. Pharmacol. Ther.89 ( 3 ), 408 – 415 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Limdi NA , WadeliusM, CavallariLet al. Warfarin pharmacogenetics: a single VKORC1 polymorphisms is predictive of dose across 3 racial groups . Blood115 ( 18 ), 3827 – 3834 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Gage BF , EbyC, JohnsonJAet al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin . Clin. Pharmacol. Ther.84 ( 3 ), 326 – 331 ( 2008a ).
   PubMed Web of Science ®Google Scholar
• Klein TE , AltmanRB, ErikssonNet al. The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data . N. Engl. J. Med.360 ( 8 ), 753 – 764 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Wadelius M , ChenLY, LindhJDet al. The largest prospective warfarin-treated cohort supports genetic forecasting . Blood113 ( 4 ), 784 – 792 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Hooper WC . Venous thromboembolism in African Americans: a literature-based commentary . Thromb. Res.125 ( 1 ), 12 – 18 ( 2010 ).
   PubMedGoogle Scholar
• Lund K , GaffneyD, SpoonerR, EtheringtonAM, TanseyP, TaitRC . Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates . Br. J. Haematol.158 ( 2 ), 256 – 261 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Carlquist JF , AndersonJL . Using pharmacogenetics in real time to guide warfarin initiation: a clinician update . Circulation124 ( 23 ), 2554 – 2559 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• CYP2C9 Gene . www.genecards.org/cgi-bin/carddisp.pl/gene=CYP2C9
   Google Scholar
• VKORC1 Gene . www.genecards.org/cgi-bin/carddisp.pl/gene=VKORC1
   Google Scholar
• Gage BF , LeskoLJ . Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues . J. Thromb. Thrombolysis25 ( 1 ), 45 – 51 ( 2008b ).
   PubMed Web of Science ®Google Scholar
• Schelleman H , ChenJ, ChenZet al. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans . Clin. Pharmacol. Ther.84 ( 3 ), 332 – 339 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Wu AH , WangP, SmithAet al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations . Pharmacogenomics9 ( 2 ), 169 – 178 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Momary KM , ShapiroNL, VianaMA, NutescuEA, HelgasoriCM, CavallariLH . Factors influencing warfarin dose requirements in African–Americans . Pharmacogenomics8 ( 11 ), 1535 – 1544 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Limdi NA , BeasleyTM, CrowleyMRet al. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African–Americans and European–Americans . Pharmacogenetics9 ( 10 ), 1445 – 1458 ( 2008b ).
   Google Scholar
• Michaud V , VanierM-C, BrouilletteDet al. Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients . Clin. Pharm. Ther.83 ( 5 ), 740 – 748 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Schelleman H , BrensingerCM, ChenJ, FinkelmanBS, RiederMJ, KimmelSE . New genetic variant that might improve warfarin dose prediction in African Americans . Br. J. Pharmacol.70 ( 3 ), 393 – 399 ( 2010 ).
   Google Scholar
• Gage BF . Pharmacogenetics-based coumarin therapy . Hematology Am. Soc. Hematol. Educ. Program467 – 473 ( 2006 ).
   PubMedGoogle Scholar
• Ramirez AH , ShiY, SchildcroutJSet al. Predicting warfarin dosage in European–Americans and African–Americans using DNA samples linked to an electronic health record . Pharmacogenomics13 ( 4 ), 407 – 418 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Mitchell C , GregersenN, KrauseA . Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population . Pharmacogenomics12 ( 7 ), 953 – 963 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Shrif NE , WonHH, LeeSTet al. Evaluation of the effect of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients . Eur. J. Clin. Pharmacol.67 ( 11 ), 1119 – 1130 ( 2011 ).
   PubMedGoogle Scholar
• Scott SA , KhasawnehR, PeterI, KornreichR, DesnickRJ . Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups . Pharmacogenetics11 ( 6 ), 781 – 791 ( 2010 ).
   Google Scholar
• Scott SA , JaremkoM, LubitzSA, KornreichR, HalperinJL, DesnickRJ . CYP2C9*8 is prevalent among African–Americans: implications for pharmacogenetic dosing . Pharmacogenetics10 ( 8 ), 1243 – 1255 ( 2009 ).
   Google Scholar
• Cavallari LH , PereraM, WadeliusMet al. Association of the GGCX (CAA) 16/17 repeat polymorphism with higher warfarin dose requirements in African–Americans . Pharmacogenet. Genomics22 ( 2 ), 152 – 158 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Perera MA , CavallariLH, LimdiNAet al. Genetic variants associated with warfarin dose in African–American individuals: a genome-wide association study . Lancet382 ( 9894 ), 790 – 796 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Peacock E , WhiteleyP . Perlegen Sciences, inc . Pharmacogenomics6 ( 4 ), 439 – 442 ( 2005 ).
   PubMedGoogle Scholar
• The International HapMap Consortium . A haplotype map of the human genome . Nature437 ( 7063 ), 1299 – 1320 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• The SeattleSNPs Program for Genomic Applications (PGA), sponsored by the University of Washington . http://pga.ga.washington.edu/gty_data_vkorc1/vkrc1.AA.clusters.txt
   Google Scholar
• Allabi AC , GalaJL, DesagerJP, HeusterspreuteM, HorsmansY . Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgium populations . Br. J. Clin. Pharmacol.56 ( 6 ), 653 – 657 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Suarez-Kurtz G , AmorimA, DamascenoAet al. VKORC1 polymorphisms in Brazilians: comparison with the Portuguese and Portuguese-speaking Africans and pharmacogenetic implications . Pharmacogenomics11 ( 9 ), 1257 – 1267 ( 2010 ).
   PubMedGoogle Scholar
• Kudzi W , DodooAN, MillsJJ . Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population . BMC Med. Genet.10, 124 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Kudzi W , AhorhorluSY, DzudzorBet al. Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population . BMC Res. Notes9 ( 1 ), 507 ( 2016 ).
   PubMedGoogle Scholar
• Allabi AC , GalaJL, HorsmansY . CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population . Pharmacogenet. Genomics15 ( 11 ), 779 – 786 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Vargens DD , DamascenoA, Petzl-ErlerML, Suarez-KurtzG . Combined CYP2C9, VKORC1 and CYP4F2 frequencies among Amerindians, Mozambicans and Brazilians . Pharmacogenomics12 ( 6 ), 769 – 772 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Dandara C , LombardZ, Du PlooyI, McLellanT, NorrisSA, RamsayM . Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity . Pharmacogenomics12 ( 12 ), 1663 – 1670 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Voora D , KoboldtDC, KingCRet al. A polymorphism in the VKORC1 regulator caluminium predicts higher warfarin dose requirements in African Americans . Clin. Pharmacol. Ther.87 ( 4 ), 445 – 451 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Wadelius M . Warfarin pharmacogenetics: it matters if you’re black or white . Blood124 ( 14 ), 2171 ( 2014 ).
   PubMedGoogle Scholar
• Alzubiedi S , SalehMI . Pharmacogenetic-guided warfarin dosing algorithm in African–Americans . J. Cardiovasc. Pharmacol.67 ( 1 ), 86 – 92 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Daneshjou R , GamazonER, BurkleyBet al. Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans . Blood124 ( 14 ), 2298 – 2305 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Suarez-Kurtz G , BottonMR . Pharmacogenomics of warfarin in populations of African descent . Br. J. Clin. Pharmacol.75 ( 2 ), 334 – 346 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Belley-Cote EP , HanifH, D’AragonFet al. Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. A systemic review and meta-analysis . Thromb. Haemost.114 ( 4 ), 768 – 777 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• PharmGKB . www.pharmgkb.org/gene/PA133787052
   Google Scholar
• Johnson JA , GongL, Whirl-CarrilloMet al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing . Clin. Pharmacol. Ther.90 ( 4 ), 625 – 629 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Warfarin dosing : http://warfarindosing.org
   Google Scholar
• Furie B . Do pharmacogenetics have a role in the dosing of vitamin K antagonists?N. Engl. J. Med.369 ( 24 ), 2345 – 2346 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kimmel SE , FrenchB, KasnerSEet al. A pharmacogenetic versus a clinical algorithm for warfarin dosing . N. Engl. J. Med.369 ( 24 ), 2283 – 2293 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Limdi NA , BrownTM, YanQet al. Race influences warfarin dose changes associated with genetic factors . Blood126 ( 4 ), 539 – 545 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Drozda K , WongS, PatelSRet al. Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans . Pharmacogenet Genomics25 ( 2 ), 73 – 81 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Johnson JA , CaudleKE, GongLet al. linical Pharmacogenetics Implementation Consortium (CPIC) guidelines for pharmacogenetics-guided warfarin dosing: 2017 update . Clin. Pharmacol. Ther.102 ( 3 ), 397 – 404 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• American College of Cardiology . “Genetically guided warfarin dosing lowers risk of some adverse events.” Science Daily. ScienceDaily, 20 March 2017 . www.sciencedaily.com/releases/2017/03/170320091104.htm
   Google Scholar